Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?

There was a time before the turn of the millennium when Robert F. Kennedy Jr. gave a full-throated accounting of himself and the things he cared about. He recalls his voice then as "unusually strong," so much so that he could fill large auditoriums with his words. The independent presidential candidate recounts those times somewhat wistfully, telling interviewers that he "can't stand" the sound of his voice today -- sometimes choked, halting and slightly tremulous. Spasmodic dysphonia, a rare neurological condition, in which an abnormality in the brain's neural network results in involuntary spasms of the muscles that open or close the vocal cords. My my voice doesn't really get tired. "I feel sorry for the people who have to listen to me," Kennedy said in a phone interview with The Times, his voice sounding as strained as it does in his public appearances.

To survive and remain competitive in today's economic and business environment, organizations must lead large-scale changes. Constant organizational change is the new normal in an ever-changing political, social, and economical atmosphere. Artificial intelligence is one of the few innovations that have the potential to assist businesses to transcend significant commercial chasms. AI has immense potential to rocket businesses above the established order and adapts to the new dynamics in business operations. The year 2016 marked the beginning of the business world's recognition of AI potential.

Simulators that can rapidly test trillions of options would accelerate the slow and costly process of human clinical trials. The magnitude of the Covid-19 pandemic will largely depend on how quickly safe and effective vaccines and treatments can be developed and tested. Many assume a widely available vaccine is years away, if ever. Others believe that a 12- to 18-month development cycle is a given. Our best bet to reduce even that record-breaking timeline is by using artificial intelligence. The problem is twofold: discovering the right set of molecules among billions of possibilities, and then waiting for clinical trials.

The magnitude of the Covid-19 pandemic will largely depend on how quickly safe and effective vaccines and treatments can be developed and tested. Many assume a widely available vaccine is years away, if ever. Others believe that a 12- to 18-month development cycle is a given. Our best bet to reduce even that record-breaking timeline is by using artificial intelligence. The problem is twofold: discovering the right set of molecules among billions of possibilities, and then waiting for clinical trials. These processes ordinarily take several years, but AI holds the key to radically shortening both.

Immune systems across the globe have been working overtime this winter as a devastating flu season has taken hold. More than 180,000 Americans have been hospitalized and 10,000 more have died in recent months, according to the CDC, while the coronavirus (now officially designated COVID-19) has spread across the globe at an alarming rate. Fears of a growing worldwide flu outbreak have even prompted the precautionary cancelling of MWC 2020 -- barely a week before it was slated to open in Barcelona. But in the near future, AI-augmented drug development could help produce vaccines and treatments fast enough to halt the spread of deadly viruses before they mutate into global pandemics. Conventional methods for drug and vaccine development are wildly inefficient.

A new flu vaccine designed by artificial intelligence has gone on trial in the United States in what researchers are claiming is a world first. Scientists at Flinders University in Australia have developed what they describe as a "turbo-charged" flu vaccine with an extra component that stimulates the human immune system to make more antibodies against the flu virus than a normal vaccine, thus making it more effective. Nikolai Petrovsky, professor of medicine at Flinders University in Australia and the lead researcher on the vaccine, said that as far as he knew this was the first time a flu vaccine had been developed using AI that had progressed to a trial in humans. He said that the use of AI had accelerated the vaccine discovery process, cut costs massively and had enabled the development of a more effective vaccine. He said using AI streamlined the vaccine development process.

For the first time ever, a human drug has been created entirely by artificial intelligence (AI). This news comes from a team at Flinders University in Australia, who claims to have created an enhanced influenza vaccine using an AI program known Search Algorithm for Ligands (SAM). Though computers have been used to make drugs before, this was the first time it was done independently by an AI system. The researchers described this drug as a flu vaccine with an added compound that better stimulates the human immune system. This addition causes more antibodies to be formed against the flu virus than with the traditional vaccination, increasing the vaccine's efficacy.

Smart speakers are becoming more and more common inside of homes, offering a convenient way to get the weather, manage your calendar, and answer any questions you may have. But this year, your Amazon Echo can also help you prepare for the upcoming flu season. Conceptualized and developed by Seattle Children's Hospital and Boston Children's Hospital, the Flu Doctor skill provides a convenient way to educate yourself (and your family) about the flu vaccine. "We know that search is increasingly going to be voice-enabled and we know increasingly more and more of us are incorporating smart speakers into our lives," Dr. Wendy Sue Swanson, general pediatrician and Chief of Digital Innovation at Seattle Children's Hospital, tells Reviewed. "The benefit of Flu Doctor is to learn more about the flu in your home, in a way that maybe you hadn't before using Alexa."

A team at Flinders University in South Australia has developed a new vaccine believed to be the first human drug in the world to be completely designed by artificial intelligence (AI). While drugs have been designed using computers before, this vaccine went one step further being independently created by an AI program called SAM (Search Algorithm for Ligands). Flinders University Professor Nikolai Petrovsky who led the development told Business Insider Australia its name is derived from what it was tasked to do: search the universe for all conceivable compounds to find a good human drug (also called a ligand). "We had to teach the AI program on a set of compounds that are known to activate the human immune system, and a set of compounds that don't work. The job of the AI was then to work out for itself what distinguished a drug that worked from one that doesn't," Petrovsky said, who is also the Research Director of Australian biotechnology company Vaxine.